BR0011521A - Composto nucleósidos de purina de 4' -c-etinila - Google Patents

Composto nucleósidos de purina de 4' -c-etinila

Info

Publication number
BR0011521A
BR0011521A BR0011521-5A BR0011521A BR0011521A BR 0011521 A BR0011521 A BR 0011521A BR 0011521 A BR0011521 A BR 0011521A BR 0011521 A BR0011521 A BR 0011521A
Authority
BR
Brazil
Prior art keywords
ethynyl
purine nucleoside
nucleoside compound
hydrogen atom
pyrimidine
Prior art date
Application number
BR0011521-5A
Other languages
English (en)
Other versions
BR0011521B1 (pt
BR0011521B8 (pt
Inventor
Hiroshi Ohrui
Eiichi Kodama
Satoru Kohgo
Hiroaki Mitsuya
Masao Matsuoka
Kenji Kitano
Original Assignee
Yamasa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamasa Corp filed Critical Yamasa Corp
Publication of BR0011521A publication Critical patent/BR0011521A/pt
Publication of BR0011521B1 publication Critical patent/BR0011521B1/pt
Publication of BR0011521B8 publication Critical patent/BR0011521B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Patente de Invenção "COMPOSTOS NUCLEóSIDOS DE PURINA DE 4'-C-ETINILA". Representados pela fórmula [I]: em que B representa uma base selecionada a partir do grupo que consiste de purina e seus derivados; X representa um átomo de hidrogênio ou um grupo hidroxila; e R representa um átomo de hidrogênio ou um resíduo de fosfato; e uma composição farmacêutica que contém qualquer dos compostos e um veículo farmaceuticamente aceitável. Preferencialmente, a composição é utilizada como agente anti-HIV ou uma droga para o tratamento da AIDS.
BRPI0011521A 1999-05-12 2000-05-11 compostos nucleósidos de purina de 4 -c-etinila BR0011521B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP13153999 1999-05-12
JP17492099 1999-06-22
JP31824699 1999-11-09
JP2000081117 2000-03-23
PCT/JP2000/003025 WO2000069877A1 (en) 1999-05-12 2000-05-11 4'-c-ethynyl purine nucleosides

Publications (3)

Publication Number Publication Date
BR0011521A true BR0011521A (pt) 2002-03-26
BR0011521B1 BR0011521B1 (pt) 2013-12-24
BR0011521B8 BR0011521B8 (pt) 2021-05-25

Family

ID=27471622

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0011521A BR0011521B8 (pt) 1999-05-12 2000-05-11 compostos nucleósidos de purina de 4 -c-etinila

Country Status (10)

Country Link
US (3) US6333315B1 (pt)
EP (2) EP1177201B1 (pt)
AT (2) ATE250623T1 (pt)
AU (2) AU4431200A (pt)
BR (1) BR0011521B8 (pt)
CA (2) CA2308192C (pt)
DE (2) DE60005501T2 (pt)
ES (1) ES2207504T3 (pt)
MX (1) MXPA01011517A (pt)
WO (2) WO2000069877A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2207504T3 (es) * 1999-05-12 2004-06-01 Yamasa Corporation Nucleosidos 4'-c-etinilpurina.
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
JP2005536440A (ja) * 2001-09-28 2005-12-02 イデニクス（ケイマン）リミテツド ４’位が修飾されたヌクレオシドを使用するフラビウイルスおよびペスチウイルスの治療のための方法および組成物
AU2003211483A1 (en) * 2002-02-15 2003-09-04 Yamasa Corporation 4'-c-cyano-2'-deoxypurine nucleosides
AU2004260630B2 (en) * 2003-02-19 2009-12-10 Masanori Baba Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
US7645459B2 (en) * 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
DE602005015466D1 (de) 2004-08-23 2009-08-27 Hoffmann La Roche Antivirale 4'-azidonucleoside
ES2617582T3 (es) 2005-09-26 2017-06-19 Gilead Pharmasset Llc 4'-Nucleósidos modificados como agentes antivirales
ES2392948T3 (es) 2006-10-10 2012-12-17 Janssen Products, L.P. Intermedio para inhibidores nucleosídicos de VHC
US20090318380A1 (en) * 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
SG11201402826YA (en) * 2011-12-22 2014-12-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG10201804835VA (en) 2013-10-11 2018-07-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
CA2998646C (en) 2015-09-23 2021-05-18 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof
US10933067B2 (en) 2016-11-16 2021-03-02 National Center For Global Health And Medicine Nucleoside derivative having physiological activity such as antiviral activity
US11040975B2 (en) 2017-12-08 2021-06-22 Merck Sharp & Dohme Corp. Carbocyclic nucleoside reverse transcriptase inhibitors
CA3087192A1 (en) * 2017-12-27 2019-07-04 Raymond F. Schinazi Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
CN112996511B (zh) * 2018-07-09 2024-08-09 默沙东有限责任公司 4’-乙炔基核苷类似物的酶促合成
JP2021536444A (ja) * 2018-08-30 2021-12-27 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Ｈｉｖ療法に有用な化合物
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
WO2021038509A1 (en) * 2019-08-28 2021-03-04 Glaxosmithkline Intellectual Property (No.2) Limited 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
JP2023518433A (ja) 2020-03-20 2023-05-01 ギリアード サイエンシーズ， インコーポレイテッド ４’－ｃ－置換－２－ハロ－２’－デオキシアデノシンヌクレオシドのプロドラッグ並びにその製造法及び使用法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2207504T3 (es) * 1999-05-12 2004-06-01 Yamasa Corporation Nucleosidos 4'-c-etinilpurina.

Also Published As

Publication number Publication date
DE60005501T2 (de) 2004-06-24
EP1177201B1 (en) 2003-09-24
US6291670B1 (en) 2001-09-18
CA2308677A1 (en) 2000-11-12
US6403568B1 (en) 2002-06-11
BR0011521B1 (pt) 2013-12-24
EP1177202B1 (en) 2003-09-24
DE60005502D1 (de) 2003-10-30
US20020022722A1 (en) 2002-02-21
WO2000069876A1 (en) 2000-11-23
CA2308192C (en) 2007-09-18
AU4431300A (en) 2000-12-05
ATE250623T1 (de) 2003-10-15
DE60005502T2 (de) 2004-06-24
EP1177202A1 (en) 2002-02-06
CA2308192A1 (en) 2000-11-12
ES2207504T3 (es) 2004-06-01
WO2000069877A1 (en) 2000-11-23
MXPA01011517A (es) 2003-08-20
AU4431200A (en) 2000-12-05
DE60005501D1 (de) 2003-10-30
BR0011521B8 (pt) 2021-05-25
EP1177201A1 (en) 2002-02-06
US6333315B1 (en) 2001-12-25
CA2308677C (en) 2007-09-18
ATE250622T1 (de) 2003-10-15

Similar Documents

Publication Publication Date Title
BR0011521A (pt) Composto nucleósidos de purina de 4' -c-etinila
BG106569A (en) Purine derivatives
AP2002002455A0 (en) 5-(2-substituted-5-heterocyclylsulphonylpyrid-3-yl)-dIhydropyrazolo[4,3-D] pyrimidin-7-ones as phosphodiesterase inhibitors.
WO2002069903A3 (en) Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
ES2175079T3 (es) Derivados de indol utiles como inhibidores de cgmp-pde.
MY141512A (en) Purine derivatives
WO1997030677A3 (en) Pentafluorobenzenesulfonamides and analogs
NO177054C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive aminopyrimidinderivater
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
TR200103395T2 (tr) 13-metil eritromisin türevleri.
GEP20084284B (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
CA2238875A1 (en) Tri-aryl ethane derivatives as pde iv inhibitors
RS20050450A (en) 2-aminocarbonyl-quinoline compounds as platelet adenosine diphosphate receptor antagonists
SE9904129D0 (sv) Novel compounds
ES2013664A6 (es) Un procedimiento para preparar derivados de nucleosidos de aciclopiramidina sustituidos en la posicion 6.
ATE157252T1 (de) 3'-azido-2',3'-dideoxy-5-methylcytidin enthaltende antivirale zusammensetzungen
BRPI9916820B8 (pt) composição compreendendo 9[2[[bis[(pivaloilóxi)metil]fosfono]metóxi]etil]adenina, comprimido ou cápsula e método
DE69911785D1 (de) Triazolo[4,5-d]pyrimidin-verbindungen
ATE285771T1 (de) Diaminotrifluoromethylpyrimidinderivate enthaltende antikrebs-zusammensetzung
AU7653300A (en) Carbocyclic nucleosides and process for obtaining such
DE69007356D1 (de) Zyklisches Tetrapeptid und Verfahren zu dessen Herstellung.
IL147307A0 (en) Indolocarbazole alkaloid derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
ES2128960A1 (es) Derivados de fluorofenil-triazinas y pirimidinas compuestos farmacologicamente activos en el sistema nervioso central.
HUP0101505A2 (hu) Barbitursavszármazékok és ezeket tartalmazó gyógyszerkészítmények csont- és porcbetegségek kezelésére és megelőzésére
CA2239053A1 (en) Diphenyl pyridyl ethane derivatives as pde iv inhibitors

Legal Events

Date Code Title Description
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]

Free format text: COMPLEMENTAR A RETRIBUICAO DA(S) 7A ANUIDADE(S), DE ACORDO COM A TABELA VIGENTE, REFERENTE A(S) GUIA(S) NO 220602446160.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: REFERENTE A RPI NO 2116 DE 26/07/2011

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AO NAO RECOLHIMENTO DA 10A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08G Application fees: restoration [chapter 8.7 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/12/2013, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/05/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 11/05/2020